

## North Yorkshire & York Area Prescribing Committee

Summary of decisions made regarding new product requests considered at a meeting of the Committee on the 4<sup>th</sup> October 2023.

### Classification of products:

- G** **Green drug** - Can be initiated and prescribed in all care settings **O**- Second line / alternative green drug.
- ASR** **Amber Specialist Recommendation drug** - Can be recommended by a specialist for initiation in primary care.
- ASI** **Amber Specialist Initiation drug** – Initiated by a specialist and transferred to primary care once the patient stabilised. In some cases there may be a further restriction for use outlined - these will be defined in each case.
- ASC** **Amber Shared Care drug** - These are specialist drugs which must be initiated by the specialist, but with the potential to transfer to primary care within written and agreed shared care protocols and according to the agreed process for transfer of care.
- R** **Red drug** - Drugs that should remain under the total responsibility of the specialist. Usually considered as “hospital only” drugs.
- BLACK** **Not Approved** - Drugs that have been considered by the APC or other approved body and are not approved for prescribing within North Yorkshire & York.
- GREY** **Not Reviewed** - Drugs that have not been reviewed by the APC yet. This usually means that no application has been received or that an application is in progress. These drugs are not normally considered appropriate for prescribing in North Yorkshire & York.



Product	Decision			Comments/notes
	Approved	Refused	Deferred	
<b>1) Requests deferred from previous meeting</b>				
<b>TA875: Semaglutide for managing overweight and obesity</b>	✓ <b>R</b>			The formulary will reflect the TAG – ICB the responsible commissioner.  Note: Referred to IPMOC due to service/commissioning implications.
<b>2) New Requests</b>				
<b>Modafinil for fatigue associated with MS</b>	✓ <b>R</b>			<b>Decision:</b> approved as an option per NICE guidance for fatigue associated with Multiple Sclerosis. This is an unlicensed indication and matches status in Humber.
<b>SSRIs for fatigue associated with MS</b>	✓ <b>ASI</b>			<b>Decision:</b> approved as an option per NICE guidance for fatigue associated with Multiple Sclerosis. This is an unlicensed indication but prescribers are familiar with the prescribing of SSRIs in general.
<b>3) New formulations &amp; extensions to use</b>				
<b>None</b>				

DECISION SUMMARY

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
<b>5) Products considered by NICE</b>				
<b>TA912: Cipaglucoasidase alfa with miglustat for treating late-onset Pompe disease</b>	✓ <b>R</b>			The formulary will reflect the TAG – NHS England is the responsible commissioner.
<b>6) Appeals against earlier decisions by the APC</b>				
None				
<b>7) Miscellaneous formulary decisions by the APC</b>				
<b>Lixisenatide discontinuation</b>	✓			Lixisenatide (Lyxumia®) 20micrograms/0.2ml solution for injection 3ml pre-filled disposable devices are being discontinued and stock will be exhausted by w/c 18th December 2023.  <b>Decision:</b> agreed to remove from formulary.

The following documents/guidelines were presented to and approved at the October 2023 meeting of the APC:

- NY&Y APC Medical Devices commissioning position.
- Antenatal anaemia management plan HDFT

The following guidelines were presented to and recommended for approval to the HNY IPMOC at the October 2023 meeting of the APC:

- Nil this month.

The following shared care guidelines were presented to and approved at the October 2023 meeting of the APC:

- NY&Y APC Azathoprine and Sirolimus shared care in renal transplant.

The following documents/guidelines were presented to the October 2023 meeting of the APC for comment:

- Nil.